JP7813775B2 - 線維症の処置のためのｔｌｒ９の阻害剤としてのイミダゾ［１，２－ａ］ピリジンおよび［１，２，４］トリアゾロ［１，５－ａ］ピリジン誘導体 - Google Patents

線維症の処置のためのｔｌｒ９の阻害剤としてのイミダゾ［１，２－ａ］ピリジンおよび［１，２，４］トリアゾロ［１，５－ａ］ピリジン誘導体

Info

Publication number
JP7813775B2
JP7813775B2 JP2023512226A JP2023512226A JP7813775B2 JP 7813775 B2 JP7813775 B2 JP 7813775B2 JP 2023512226 A JP2023512226 A JP 2023512226A JP 2023512226 A JP2023512226 A JP 2023512226A JP 7813775 B2 JP7813775 B2 JP 7813775B2
Authority
JP
Japan
Prior art keywords
phenyl
pyridine
methylsulfonyl
imidazo
mmol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2023512226A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2022040259A5 (https=
JP2023538393A5 (https=
JP2023538393A (ja
Inventor
エス ユン，デイビッド
レゲイロ－レン，アリシア
ピー デグナン，アンドリュー
ウー，ガン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of JP2023538393A publication Critical patent/JP2023538393A/ja
Publication of JPWO2022040259A5 publication Critical patent/JPWO2022040259A5/ja
Publication of JP2023538393A5 publication Critical patent/JP2023538393A5/ja
Application granted granted Critical
Publication of JP7813775B2 publication Critical patent/JP7813775B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
JP2023512226A 2020-08-19 2021-08-18 線維症の処置のためのｔｌｒ９の阻害剤としてのイミダゾ［１，２－ａ］ピリジンおよび［１，２，４］トリアゾロ［１，５－ａ］ピリジン誘導体 Active JP7813775B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063067452P 2020-08-19 2020-08-19
US63/067,452 2020-08-19
PCT/US2021/046420 WO2022040259A1 (en) 2020-08-19 2021-08-18 Imidazo[1,2-a]pyridine and [1,2,4]triazolo[1,5-a]pyridine derivatives as tlr9 inhibitors for the treatment of fibrosis

Publications (4)

Publication Number Publication Date
JP2023538393A JP2023538393A (ja) 2023-09-07
JPWO2022040259A5 JPWO2022040259A5 (https=) 2024-08-26
JP2023538393A5 JP2023538393A5 (https=) 2024-08-26
JP7813775B2 true JP7813775B2 (ja) 2026-02-13

Family

ID=77693624

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023512226A Active JP7813775B2 (ja) 2020-08-19 2021-08-18 線維症の処置のためのｔｌｒ９の阻害剤としてのイミダゾ［１，２－ａ］ピリジンおよび［１，２，４］トリアゾロ［１，５－ａ］ピリジン誘導体

Country Status (13)

Country Link
US (1) US12486267B2 (https=)
EP (1) EP4200297A1 (https=)
JP (1) JP7813775B2 (https=)
KR (1) KR20230053644A (https=)
CN (1) CN116096717B (https=)
AR (1) AR123281A1 (https=)
AU (1) AU2021328575A1 (https=)
BR (1) BR112023002737A2 (https=)
CA (1) CA3190065A1 (https=)
IL (1) IL300727A (https=)
MX (1) MX2023001885A (https=)
TW (1) TW202227432A (https=)
WO (1) WO2022040259A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11807622B2 (en) 2019-01-30 2023-11-07 Insilico Medicine Ip Limited TLR 9 inhibitors
US20250163054A1 (en) * 2022-02-18 2025-05-22 Bristol-Myers Squibb Company Substituted bicyclic heteroaryl compounds useful as inhibitors of tlr9
CN120230100B (zh) * 2025-05-30 2025-09-05 中国药科大学 一种咪唑并[1,2-a]吡嗪或咪唑并[1,2-a]吡啶类化合物及其医药用途

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014500331A (ja) 2010-12-22 2014-01-09 ヘングルイ（ユーエスエイ），リミテッド ２−アリールイミダゾ［１，２−ｂ］ピリダジン、２−フェニルイミダゾ［１，２−ａ］ピリジンおよび２−フェニルイミダゾ［１，２−ａ］ピラジン誘導体
WO2018165112A1 (en) 2017-03-09 2018-09-13 Oncotherapy Science, Inc. Bicyclic compound and use thereof for inhibiting histone methyltransferase
JP2018531244A (ja) 2015-09-29 2018-10-25 オンコセラピー・サイエンス株式会社 Ｓｕｖ３９ｈ２を阻害するための二環式化合物およびその使用
JP2021503004A (ja) 2017-11-14 2021-02-04 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 置換インドール化合物
JP2021506858A (ja) 2017-12-18 2021-02-22 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ ４−アザインドール化合物

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006113458A1 (en) 2005-04-15 2006-10-26 Bristol-Myers Squibb Company Heterocyclic inhibitors of protein arginine methyl transferases
GB0602178D0 (en) 2006-02-03 2006-03-15 Merck Sharp & Dohme Therapeutic treatment
CA2648652A1 (en) 2006-04-04 2007-10-11 Myriad Genetics, Inc. Compounds for diseases and disorders
US20100035756A1 (en) 2006-07-12 2010-02-11 Syngenta Limited Triazolophyridine derivatives as herbicides
EP2205085A1 (en) 2007-09-25 2010-07-14 Merck Sharp & Dohme Corp. 2-aryl or heteroaryl indole derivatives
US8785489B2 (en) 2008-10-17 2014-07-22 Boehringer Ingelheim International Gmbh Heteroaryl substituted indole compounds useful as MMP-13 inhibitors
RU2012116207A (ru) 2009-09-24 2013-10-27 Ф.Хоффманн-Ля Рош Аг Производные индола в качестве модуляторов crac
US9193724B2 (en) 2011-09-22 2015-11-24 Merck Sharp & Dohme Corp. Triazolopyridyl compounds as aldosterone synthase inhibitors
WO2013092467A1 (en) 2011-12-20 2013-06-27 F. Hoffmann-La Roche Ag 7-azaindole inhibitors of crac
US20130158066A1 (en) 2011-12-20 2013-06-20 Hoffmann-La Roche Inc. 4-azaindole inhibitors of crac
WO2013156431A1 (en) 2012-04-17 2013-10-24 Syngenta Participations Ag Pesticidally active pyridyl- and pyrimidyl- substituted thiazole and thiadiazole derivatives
EP2862853B1 (en) 2012-06-18 2020-01-22 Sumitomo Chemical Co., Ltd Fused heterocyclic compound
CN105992766A (zh) 2013-12-13 2016-10-05 武田药品工业株式会社 作为tlr抑制剂的吡咯并[3,2-c]吡啶衍生物
EP3194394B1 (en) 2014-09-16 2019-01-09 Syngenta Participations AG Pesticidally active tetracyclic derivatives with sulphur containing substituents
US10071079B2 (en) 2016-06-29 2018-09-11 Bristol-Myers Squibb Company [1,2,4]triazolo[1,5-a]pyridinyl substituted indole compounds
BR112019001270A2 (pt) 2016-07-30 2019-04-30 Bristol-Myers Squibb Company compostos indol substituídos com dimetoxifenila como inibidores de tlr7, tlr8 ou tlr9
JP7028861B2 (ja) 2016-09-09 2022-03-02 ブリストル－マイヤーズ スクイブ カンパニー ピリジル置換のインドール化合物
US11370794B2 (en) * 2016-11-11 2022-06-28 Dynavax Technologies Corporation Toll-like receptor antagonist compounds and methods of use
KR102688509B1 (ko) 2017-08-04 2024-07-24 브리스톨-마이어스 스큅 컴퍼니 [1,2,4]트리아졸로[4,3-a]피리디닐 치환된 인돌 화합물
WO2019028302A1 (en) 2017-08-04 2019-02-07 Bristol-Myers Squibb Company SUBSTITUTED INDOLE COMPOUNDS USEFUL AS TLR7 / 8/9 INHIBITORS
KR102781141B1 (ko) 2017-12-15 2025-03-13 브리스톨-마이어스 스큅 컴퍼니 치환된 인돌 에테르 화합물
JP7304352B2 (ja) 2017-12-19 2023-07-06 ブリストル－マイヤーズ スクイブ カンパニー ６－アザインドール化合物
MX2020005462A (es) 2017-12-19 2020-09-07 Bristol Myers Squibb Co Compuestos de indol sustituidos utiles como inhibidores de receptores tipo toll (tlr).
WO2019126081A1 (en) 2017-12-19 2019-06-27 Bristol-Myers Squibb Company Amide substituted indole compounds useful as tlr inhibitors
KR102730859B1 (ko) 2017-12-20 2024-11-15 브리스톨-마이어스 스큅 컴퍼니 아릴 및 헤테로아릴 치환된 인돌 화합물
EP3728218B1 (en) 2017-12-20 2021-12-01 Bristol-Myers Squibb Company Amino indole compounds useful as tlr inhibitors
SG11202005733QA (en) 2017-12-20 2020-07-29 Bristol Myers Squibb Co Diazaindole compounds
CN114981276B (zh) * 2020-01-09 2024-09-27 住友化学株式会社 杂环化合物和含有其的有害节肢动物防除组合物

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014500331A (ja) 2010-12-22 2014-01-09 ヘングルイ（ユーエスエイ），リミテッド ２−アリールイミダゾ［１，２−ｂ］ピリダジン、２−フェニルイミダゾ［１，２−ａ］ピリジンおよび２−フェニルイミダゾ［１，２−ａ］ピラジン誘導体
JP2018531244A (ja) 2015-09-29 2018-10-25 オンコセラピー・サイエンス株式会社 Ｓｕｖ３９ｈ２を阻害するための二環式化合物およびその使用
WO2018165112A1 (en) 2017-03-09 2018-09-13 Oncotherapy Science, Inc. Bicyclic compound and use thereof for inhibiting histone methyltransferase
JP2021503004A (ja) 2017-11-14 2021-02-04 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 置換インドール化合物
JP2021506858A (ja) 2017-12-18 2021-02-22 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ ４−アザインドール化合物

Also Published As

Publication number Publication date
EP4200297A1 (en) 2023-06-28
TW202227432A (zh) 2022-07-16
CN116096717A (zh) 2023-05-09
WO2022040259A1 (en) 2022-02-24
US12486267B2 (en) 2025-12-02
CN116096717B (zh) 2026-04-10
IL300727A (en) 2023-04-01
KR20230053644A (ko) 2023-04-21
US20240067638A1 (en) 2024-02-29
BR112023002737A2 (pt) 2023-03-14
AU2021328575A1 (en) 2023-03-16
AR123281A1 (es) 2022-11-16
JP2023538393A (ja) 2023-09-07
CA3190065A1 (en) 2022-02-24
MX2023001885A (es) 2023-03-10

Similar Documents

Publication Publication Date Title
US12492188B2 (en) 1H-benzo[D]imidazole derivatives as TLR9 inhibitors for the treatment of fibrosis
US12590091B2 (en) 1H-pyrrolo[3,2-C]pyridine and 1H-pyrrolo[2,3-C]pyridine derivatives as TLR9 inhibitors for the treatment of fibrosis
JP7813775B2 (ja) 線維症の処置のためのｔｌｒ９の阻害剤としてのイミダゾ［１，２－ａ］ピリジンおよび［１，２，４］トリアゾロ［１，５－ａ］ピリジン誘導体
JP2023539136A (ja) Ｔｌｒ９阻害剤として有用な置換ヘテロアリール化合物
EA050655B1 (ru) Замещенные бициклические соединения, пригодные для применения в качестве ингибиторов tlr9
US20250177363A1 (en) Substituted imidazopyridinyl compounds useful as inhibitors of tlr9
US20250163054A1 (en) Substituted bicyclic heteroaryl compounds useful as inhibitors of tlr9
EP4615572A1 (en) Substituted benzimidazole compounds useful as inhibitors of tlr9

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240816

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240816

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20241115

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250624

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20250626

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250716

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251021

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251030

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20260120

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20260202

R150 Certificate of patent or registration of utility model

Ref document number: 7813775

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150